The short answer is no.

The conclusion of Schmeling et al. [1]

“In conclusion, the results suggest the existence of a batch-dependent safety signal for the BNT162b2 vaccine, …”

does not follow from their analysis.

Let me explain why.

They assign reported adverse effects (AEs) to vaccine batches, and make and interpret graphs of number of batch-assigned AEs versus number of vaccine doses per batch, delivered in Denmark between 27 December 2020 and 11 January 2022. Each point on such a graph (for a given AE type or severity) is for one of the 52 batches used in Denmark in this period.

They show the resulting graph only for all-AEs, irrespective of type or severity (their Figure 1). They admit “Compared to the rates of all SAEs, serious SAEs and SAE-related deaths per 1000 doses were much less frequent and numbers of these SAEs per 1000 doses displayed considerably greater variability between batches, with lesser separation between the three trendlines,” but they do not show those graphs.

That is the full extent of their analysis. In doing this, they exclude all the information about the subjects experiencing the AEs, such as age and sex; and all the information about the injections, such as the date of the injection. They are blind to virtually everything except what is needed to make the batch assignment for each AE.

This blindness by design is acknowledged as: “in the present study, … , demographics of SAE cases, … , were not examined.”

This is a recipe for studying artifacts arising from invisible factors.

link

Researchers at Gladstone Institutes led by Senior Investigator Katerina Akassoglou, Ph.D., showed that exposure to blood leaking into the brain turns on harmful genes in microglia, transforming them into toxic cells that can destroy neurons.

The scientists discovered that a blood protein called fibrin—which normally aids blood clotting—is responsible for turning on the detrimental genes in microglia, both in Alzheimer’s disease and multiple sclerosis. The findings, published in the journal Nature Immunology, suggest that counteracting the blood toxicity caused by fibrin can protect the brain from harmful inflammation and loss of neurons in neurological diseases.

“Our study answers, for the first time in a comprehensive way, how blood that leaks into the brain hijacks the brain’s immune system to cause toxic effects in brain diseases,” says Akassoglou, who is also director of the Center for Neurovascular Brain Immunology at Gladstone and a professor of neurology at UC San Francisco (UCSF). “Knowing how blood affects the brain could help us develop innovative treatments for neurological diseases.”

link

Over 10,000 categories of nearly 1.6 million adverse events – many of them serious and debilitating – brought to you by Pfizer!

You might not have heard it in the news, but in recent months, Pfizer’s pharmacovigilance documents requested by the European Union’s drug regulator, the European Medicines Agency, have been released. They show that Pfizer knew about a sickening level of injury early on. An August 2022 document shows that the company already had observed the following scope of vaccine injury:

• 508,351 individual case reports of adverse events containing 1,597,673 events;
• One-third of the AEs were classified as serious, well above the standard for safety signals usually pegged at 15%;
• Women reported AEs at three times the rate of men;
• 60% of cases were reported with either “outcome unknown” or “not recovered,” so many of the injuries were not transient;

Highest number of cases occurred in the 31-50 year age group, and 92% did not have any comorbidities, which makes it very likely it was the vaccine causing such widespread, sudden injury.

link

Abstract

Less than a year after the global emergence of the coronavirus SARS-CoV-2, a novel vaccine platform based on mRNA technology was introduced to the market. Globally, around 13.38 billion COVID-19 vaccine doses of diverse platforms have been administered. To date, 72.3% of the total population has been injected at least once with a COVID-19 vaccine. As the immunity provided by these vaccines rapidly wanes, their ability to prevent hospitalization and severe disease in individuals with comorbidities has recently been questioned, and increasing evidence has shown that, as with many other vaccines, they do not produce sterilizing immunity, allowing people to suffer frequent re-infections. Additionally, recent investigations have found abnormally high levels of IgG4 in people who were administered two or more injections of the mRNA vaccines. HIV, Malaria, and Pertussis vaccines have also been reported to induce higher-than-normal IgG4 synthesis. Overall, there are three critical factors determining the class switch to IgG4 antibodies: excessive antigen concentration, repeated vaccination, and the type of vaccine used. It has been suggested that an increase in IgG4 levels could have a protecting role by preventing immune over-activation, similar to that occurring during successful allergen-specific immunotherapy by inhibiting IgE-induced effects. However, emerging evidence suggests that the reported increase in IgG4 levels detected after repeated vaccination with the mRNA vaccines may not be a protective mechanism; rather, it constitutes an immune tolerance mechanism to the spike protein that could promote unopposed SARS-CoV2 infection and replication by suppressing natural antiviral responses. Increased IgG4 synthesis due to repeated mRNA vaccination with high antigen concentrations may also cause autoimmune diseases, and promote cancer growth and autoimmune myocarditis in susceptible individuals.

link